NO976122D0 - AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes - Google Patents

AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes

Info

Publication number
NO976122D0
NO976122D0 NO976122A NO976122A NO976122D0 NO 976122 D0 NO976122 D0 NO 976122D0 NO 976122 A NO976122 A NO 976122A NO 976122 A NO976122 A NO 976122A NO 976122 D0 NO976122 D0 NO 976122D0
Authority
NO
Norway
Prior art keywords
antibody
fas ligand
fas
apoptosis
assay method
Prior art date
Application number
NO976122A
Other languages
English (en)
Other versions
NO976122L (no
NO324120B1 (no
Inventor
Kamon Shirakawa
Tomokazu Matsusue
Shigekazu Nagata
Man Sung Co
Maximiliano Vasquez
Original Assignee
Mochida Pharm Co Ltd
Osaka Bioscience Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/649,100 external-priority patent/US6114507A/en
Application filed by Mochida Pharm Co Ltd, Osaka Bioscience Inst filed Critical Mochida Pharm Co Ltd
Publication of NO976122D0 publication Critical patent/NO976122D0/no
Publication of NO976122L publication Critical patent/NO976122L/no
Publication of NO324120B1 publication Critical patent/NO324120B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19976122A 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene. NO324120B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18848095 1995-06-30
US08/649,100 US6114507A (en) 1995-06-30 1996-05-17 Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
PCT/JP1996/001820 WO1997002290A1 (en) 1995-06-30 1996-07-01 ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME

Publications (3)

Publication Number Publication Date
NO976122D0 true NO976122D0 (no) 1997-12-29
NO976122L NO976122L (no) 1998-02-27
NO324120B1 NO324120B1 (no) 2007-08-27

Family

ID=26504954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19976122A NO324120B1 (no) 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene.

Country Status (8)

Country Link
EP (1) EP0842948B1 (no)
JP (1) JP3925663B2 (no)
CN (1) CN1196733A (no)
AU (1) AU724856B2 (no)
CA (1) CA2225852C (no)
NO (1) NO324120B1 (no)
NZ (1) NZ311174A (no)
WO (1) WO1997002290A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725329B2 (en) 1996-09-02 2000-10-12 Ko Okumura Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
WO1999024069A1 (fr) 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Medicaments preventifs et therapeutiques pour des affections pulmonaires diffuses
US6562342B1 (en) 1998-02-06 2003-05-13 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for inflammatory intestinal disease
CA2328601A1 (en) * 1998-05-14 1999-11-18 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hepatic cirrhosis
US6759041B1 (en) 1998-05-29 2004-07-06 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for autoimmune demyelinating diseases
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4734739B2 (ja) * 2000-09-29 2011-07-27 東レ株式会社 哺乳動物のガン抑制方法
WO2003079750A2 (en) * 2002-03-21 2003-10-02 Eli Lilly And Company ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
US7371383B2 (en) * 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
JP4764818B2 (ja) * 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
ES2523992T3 (es) 2006-12-28 2014-12-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
EP2231708B1 (en) * 2007-12-12 2015-04-08 Pincell Srl Remedies for pemphigus containing anti-fas ligand antibodies
EP2246426A4 (en) 2008-01-29 2011-08-10 Inst Antibodies Co Ltd COMPOSITION FOR THE NEUTRALIZATION OF BOTULINUS TOXIN TYPE-A AND HUMAN ANTIBODIES AGAINST BOTULINUS TOXIN TYPE-A
JP5773882B2 (ja) 2008-12-12 2015-09-02 ピンチェル ソチエタ・レスポンサビリタ・リミタータＰｉｎＣｅｌｌ ｓｒｌ 抗ＦａｓＬリガンド抗体を含有する天疱瘡用治療薬
US11369572B2 (en) * 2009-07-21 2022-06-28 Queen Mary & Westfield College Fas (Apo-1,CD95) targeted platforms for intracellular drug delivery
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
DK3140653T3 (da) * 2014-05-08 2022-06-20 Novodiax Inc Direkte immunhistokemianalyse
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
AU2016325482B2 (en) 2015-09-23 2020-09-03 Apogenix Ag Anti-CD95L antibody
EP3592392B1 (en) * 2017-03-10 2023-09-13 University of Louisville Research Foundation, Inc. Fasl-engineered biomaterials with immunomodulatory function
CN116888257A (zh) * 2022-01-21 2023-10-13 北京三诺佳邑生物技术有限责任公司 特异性识别FasL的抗体及其应用
US20250257141A1 (en) 2022-04-26 2025-08-14 Hoffmann-La Roche Inc. Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
NZ275711A (en) 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
JPH09508009A (ja) * 1994-01-07 1997-08-19 イミュネックス・コーポレーション Ｆａｓ抗原を結合するリガンド
WO1996029350A1 (en) 1995-03-20 1996-09-26 Sumitomo Electric Industries, Ltd. MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME

Also Published As

Publication number Publication date
EP0842948B1 (en) 2009-04-22
NO976122L (no) 1998-02-27
AU724856B2 (en) 2000-10-05
JP3925663B2 (ja) 2007-06-06
CA2225852A1 (en) 1997-01-23
EP0842948A4 (en) 2004-12-15
WO1997002290A1 (en) 1997-01-23
CA2225852C (en) 2009-04-14
NZ311174A (en) 1999-04-29
CN1196733A (zh) 1998-10-21
AU6243596A (en) 1997-02-05
EP0842948A1 (en) 1998-05-20
NO324120B1 (no) 2007-08-27

Similar Documents

Publication Publication Date Title
NO976122D0 (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
Plotz et al. Assignment of direct and facilitated hemolytic plaques in mice to specific immunoglobulin classes
Schuurman et al. Normal human immunoglobulin G4 is bispecific: it has two different antigen‐combining sites
Winkelhake et al. Aglycosylantibody. Effects of exoglycosidase treatments on autochthonous antibody survival time in the circulation.
Morell et al. Human IgG subclasses in maternal and fetal serum
DE69637909D1 (de) ANTI-Fas-LIGAND ANTIKÖRPER UND TESTMETHODE UNTER VERWENDUNG DERSELBEN
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
Lesley et al. Antigen receptor molecules: inhibition by antiserum against kappa light chains
BG101024A (bg) Моноклонално антитяло срещу сd44v6
DK0552296T3 (da) Monoklonale antistoffer fra mus
JP7835815B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
Zhang et al. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
KR960010024A (ko) 류머티즘 치료제
SE8300320D0 (sv) Monoclonal antibody formulation for diagnostic use
DE69431526T2 (de) Ligand fähig zur bindung an der adenosinedeaminase-bindungsstelle von cd26
Sulica et al. Effect of protein A of Staphylococcus aureus on the binding of monomeric and polymeric IgG to Fc receptor-bearing cells
Martens et al. Increased circulating interleukin‐6 (IL‐6) activity in endotoxin‐challenged mice pretreated with anti‐IL‐6 antibody is due to IL‐6 accumulated in antigen‐antibody complexes
Blake et al. Allosteric binding properties of a monoclonal antibody and its Fab fragment
Yu et al. A monoclonal antibody with anti‐D–like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects
DE69018968D1 (de) BLUTGERINNUNGSFAKTOR BETA XIIa MONOKLONALE ANTIKÖRPER UND IMMUNANALYSE.
Olsen et al. Unique antigenic determinants (idiotypes) used as markers in a patient with macroglobulinemia and urticaria: similar idiotypes demonstrated in the skin and on peripheral blood lymphocytes
Ezzatifar et al. Large scale generation and characterization of anti-human IgA monoclonal antibody in ascitic fluid of BALB/c mice
BG96346A (bg) Специфични свързващи вещества
DE2853453C2 (no)